Thrombocytopenia is noted in corona virus disease-2019 (COVID-19) with a prevalence of 5% to 41%, and has been observed to be associated with inferior outcomes. The pathogenesis of thrombocytopenia in COVID-19 is unique and differs from other viral syndromes in terms of clinical presentation and causative mechanisms. Platelets act as both targets and the initial defense against severe acute respiratory syndrome-coronavirus 2 and work in concert with the underlying thrombophilic mechanisms to modulate the final disease phenotype. Understanding these mechanisms may possibly allow targeting of a key component of COVID-19 pathogenesis. We provide a focused review of the current mechanisms implicated in development of thrombocytopenia in COVID-19 and therapeutic implications of the same.

中文翻译：

---

COVID-19 中的血小板减少症：目前对机制和临床意义理解的重点总结。

血小板减少症在 2019 年冠状病毒病 (COVID-19) 中出现，患病率为 5% 至 41%，并已观察到与较差的结果相关。COVID-19 血小板减少症的发病机制是独特的，在临床表现和致病机制方面与其他病毒综合征不同。血小板既是针对严重急性呼吸系统综合症冠状病毒 2 的靶标，也是其初始防御，并与潜在的血栓形成机制协同工作，以调节最终的疾病表型。了解这些机制可能允许针对 COVID-19 发病机制的一个关键组成部分。我们重点回顾了与 COVID-19 中血小板减少症发展有关的当前机制及其治疗意义。